Hormonal management after risk-reducing surgery in BRCA-mutated triple-negative breast cancer survivors

Sep 22, 2026

Premenopausal women with BRCA1 or BRCA2 mutations are often advised to undergo risk-reducing bilateral salpingo-oophorectomy (BSO) to lower ovarian cancer risk, but the resulting abrupt estrogen deprivation causes premature menopause. Consequences include vasomotor symptoms, urogenital atrophy, and long-term risks such as osteoporosis, cardiovascular disease, and cognitive decline. While hormone replacement therapy (HRT) is the most effective intervention, its use in triple-negative breast cancer (TNBC) survivors is complex because early evidence suggested higher recurrence risk. This review addresses whether HRT is appropriate after BSO for BRCA carriers with TNBC history and summarizes guideline and expert recommendations.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages9

Reading Time23 min

AccessFree to download

Abstract

Guideline recommendations and the risk of early estrogen deprivation

Coronary artery disease and cardiovascular mortality after early menopause

Bone loss and fracture risk after early estrogen deprivation

International guideline positions (NCCN, ESMO, AGO)

Journal of Cancer Research and Clinical Oncology (2026) 152:60 [https://doi.org/10.1007/s00432-026-06425-9](https://doi.org/10.1007/s00432-026-06425-9) REVIEW Hormonal management after risk-reducing surgery in BRCA-mutated triple-negative breast cancer survivors Inna Jörg1 · Dimitrios Chronas1 Received: 11 May 2025 / Accepted: 12 January 2026 © The Author(s) 2026 Abstract Premenopausal women carrying a BRCA1 or BRCA2 mutation are frequently advised to undergo risk-reducing bilateral salpingo-oophorectomy (BSO) to lower their significantly increased lifetime risk of ovarian cancer. However, this procedure induces abrupt estrogen deprivation, resulting in premature menopause with well-documented consequences including vasomotor symptoms (e.g., hot flashes, night sweats), urogenital atrophy, and long-term risks such as osteoporosis, cardiovascular disease, and cognitive decline (Nelson in Lancet 371(9614):760–770, 2008; Shuster et al. in Maturitas 65(2):161–166, 2010). To alleviate symptoms and prevent sequelae, hormone replacement therapy (HRT) remains the most effective intervention. However, the issue becomes complex when the patient has a personal history of triple-negative breast cancer (TNBC) . Although TNBC lacks hormone receptor expression, systemic HRT has traditionally been contraindicated in breast cancer survivors, as early studies indicated an increased risk of recurrence with hormone therapy, even in receptor-negative subtypes (Kenemans et al. Lancet Oncol 10(2):135–146, 2009a) . This leads to a critical question: Is HRT appropriate in BRCA mutation carriers with a history ofTNBC following BSO, and if so, under what clinical conditions? What do current international guidelines, evidence, and expert recommendations suggest? Keywords BRCA mutation · Adnexectomy · Harmone replacement theraphy Guideline recommendations and the risk of early estrogen deprivation Multiple large-scale studies have demonstrated that menopause before the age of 40—whether spontaneous or surgically induced—is associated with a significantly increased risk of cardiovascular disease and osteoporotic fractures. A meta-analysis of 32 cohort studies encompassing over 300,000 women (Zhu et al., Lancet Public Health, 2019) revealed that women who experienced menopause before the age of 40 had a 1.5-fold increased risk of developing coronary artery disease (CAD). Moreover, their risk of myocardial infarction was elevated by approximately 40–60%, depending on the presence of additional cardiovascular risk factors. The study further demonstrated that the risk of CAD 􀀍 Inna Jörg [inna.joerg@spitalzollikerberg.ch](inna.joerg@spitalzollikerberg.ch) Dimitrios Chronas [Dimitrios.Chronas@spitalzollikerberg.ch](Dimitrios.Chronas@spitalzollikerberg.ch) 1 Spital Zollikerberg, Zollikerberg, Switzerland increases incrementally with each 5-year decrease in age at menopause (Parker et al. 2009) . These findings were supported by the Nurses’ Health Study, a large prospective cohort from the United States. Women who underwent surgical menopause prior to age 40 and did not receive hormone replacement therapy (HRT) exhibited a nearly twofold increased risk of cardiovascular mortality compared to age-matched women with natural menopause (Shuster et al. 2008) . These associations are thought to be primarily driven by the loss of estrogen’s protective vascular effects, including favorable modulation of lipid profiles, endothelial function, and prevention of atherosclerotic plaque formation (Bjelland et al. 2020) . Similarly, early estrogen deprivation is a well-established risk factor for rapid bone loss and fragility fractures. Women experiencing menopause before age 40 may lose 2–3% of their bone mineral density annually, especially in trabecular bone-rich sites such as the lumbar spine and proximal femur (Bjelland et al. 2020) . A Swedish population-based cohort study (2020) found that women with early menopause had a 1.3- to 1.8-f

FAQs

Why is hormone replacement therapy considered after risk-reducing BSO in BRCA1/2 carriers?

BSO induces abrupt estrogen deprivation and premature menopause, which leads to vasomotor symptoms, urogenital atrophy, and long-term risks including osteoporosis and cardiovascular disease. HRT is described as the most effective intervention to alleviate symptoms and prevent sequelae.

What makes HRT use difficult for BRCA mutation carriers with a history of triple-negative breast cancer?

Although TNBC lacks hormone receptor expression, systemic HRT has traditionally been contraindicated in breast cancer survivors. Early studies suggested an increased risk of recurrence with hormone therapy even in receptor-negative subtypes, leading to uncertainty about appropriateness and clinical conditions.

What do major international guidelines generally recommend for BRCA carriers without prior breast cancer?

Guidelines are described as unanimous that short-term HRT after premenopausal risk-reducing BSO should be considered or recommended in BRCA mutation carriers without a personal history of breast cancer, with continuation until natural menopause age and individualized considerations beyond age 50.

Sep 22, 2026

Uploaded by Genevieve